OMERS ADMINISTRATION Corp Invests $1.57 Million in Aurinia Pharmaceuticals Inc $AUPH

OMERS ADMINISTRATION Corp acquired a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 92,700 shares of the biotechnology company’s stock, valued at approximately $1,573,000. OMERS ADMINISTRATION Corp owned 0.07% of Aurinia Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. BOK Financial Private Wealth Inc. acquired a new stake in Aurinia Pharmaceuticals during the 4th quarter worth approximately $32,000. Global Retirement Partners LLC acquired a new position in shares of Aurinia Pharmaceuticals in the second quarter worth $41,000. Quantbot Technologies LP acquired a new position in shares of Aurinia Pharmaceuticals in the second quarter worth $45,000. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth $48,000. Finally, Frazier Financial Advisors LLC increased its position in shares of Aurinia Pharmaceuticals by 411.9% during the first quarter. Frazier Financial Advisors LLC now owns 3,471 shares of the biotechnology company’s stock worth $51,000 after acquiring an additional 2,793 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Stock Performance

Shares of AUPH stock opened at $16.54 on Thursday. The company has a market cap of $2.20 billion, a P/E ratio of 7.22 and a beta of 1.42. The firm has a fifty day moving average price of $15.98 and a 200 day moving average price of $15.47. The company has a current ratio of 5.42, a quick ratio of 4.97 and a debt-to-equity ratio of 0.07. Aurinia Pharmaceuticals Inc has a 12 month low of $10.34 and a 12 month high of $19.25.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, August 6th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.24 by $0.04. The company had revenue of $58.57 million for the quarter, compared to analysts’ expectations of $80.45 million. Aurinia Pharmaceuticals had a return on equity of 26.11% and a net margin of 100.84%. Sell-side analysts predict that Aurinia Pharmaceuticals Inc will post 0.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently issued reports on AUPH. Zacks Research lowered Aurinia Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, July 21st. Wall Street Zen downgraded Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Royal Bank Of Canada lifted their price objective on Aurinia Pharmaceuticals from $15.00 to $16.00 and gave the company a “sector perform” rating in a research note on Friday, August 7th. Weiss Ratings reissued a “hold (c+)” rating on shares of Aurinia Pharmaceuticals in a research report on Wednesday, August 12th. Finally, Bloom Burton upgraded shares of Aurinia Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $17.67.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CEO Kevin Tang bought 206,005 shares of the firm’s stock in a transaction that occurred on Tuesday, June 2nd. The stock was purchased at an average price of $15.28 per share, for a total transaction of $3,147,756.40. Following the completion of the purchase, the chief executive officer directly owned 13,044,106 shares in the company, valued at $199,313,939.68. This trade represents a 1.60% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last quarter, insiders bought 814,606 shares of company stock worth $12,455,129. 10.40% of the stock is currently owned by company insiders.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.